Please login to the form below

Not currently logged in
Email:
Password:

regulatory decisions

This page shows the latest regulatory decisions news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends eight new medicines for EU approval

CHMP recommends eight new medicines for EU approval

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisations for a total of eight new drugs in its June decisions. .

Latest news

More from news
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The deal was announced in June 2019 and took months to go through the antitrust regulatory process, but according to AbbVie – which agreed a massive $30bn bond issue to help finance ... BMS has warned its drug will be under pressure next year, but says

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    Several clinical programmes have advanced to late-stage development with regulatory decisions pending or on the horizon. ... Research also included a global review of launch dates and regulatory information related to several cell and gene therapies.

  • The evolution of real-world studies The evolution of real-world studies

    regulatory decisions for drugs including Pfizer’s Ibrance. ... The EMA expanded on its approach to RWE through a document detailing how it sees regulatory science evolving through to 2025.

  • The real-world data conundrum The real-world data conundrum

    Similarly, regulators are now increasingly growing to appreciate that real-world data, typically collected for non-regulatory purposes in electronic medical records, registries and administrative and claims databases, may provide new ... Indicatively, in

  • Is your multichannel having the desired impact on both your customer and business? Is your multichannel having the desired impact on both your customer and business?

    The life sciences have some unique characteristics in how 'purchasing' decisions are made, the regulatory environment and the fact there are limited post 'sale' touch points to build the experience over

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....